CA2435121A1 - Histamine receptor antagonists - Google Patents

Histamine receptor antagonists Download PDF

Info

Publication number
CA2435121A1
CA2435121A1 CA002435121A CA2435121A CA2435121A1 CA 2435121 A1 CA2435121 A1 CA 2435121A1 CA 002435121 A CA002435121 A CA 002435121A CA 2435121 A CA2435121 A CA 2435121A CA 2435121 A1 CA2435121 A1 CA 2435121A1
Authority
CA
Canada
Prior art keywords
histamine
receptor
antagonist
disease
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002435121A
Other languages
English (en)
French (fr)
Inventor
Stephen Jenkinson
Mark Anthony O'reilly
Michael Andrew Trevethick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2435121A1 publication Critical patent/CA2435121A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002435121A 2001-01-17 2002-01-10 Histamine receptor antagonists Abandoned CA2435121A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0101223.6A GB0101223D0 (en) 2001-01-17 2001-01-17 Histamine receptor antagonists
GB0101223.6 2001-01-17
PCT/IB2002/000042 WO2002056871A2 (en) 2001-01-17 2002-01-10 Histamine receptor antagonists

Publications (1)

Publication Number Publication Date
CA2435121A1 true CA2435121A1 (en) 2002-07-25

Family

ID=9906993

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002435121A Abandoned CA2435121A1 (en) 2001-01-17 2002-01-10 Histamine receptor antagonists

Country Status (31)

Country Link
EP (1) EP1353657A1 (ja)
JP (1) JP2004517883A (ja)
KR (1) KR20030069216A (ja)
CN (1) CN1486178A (ja)
AP (1) AP2002002401A0 (ja)
AR (1) AR032101A1 (ja)
BG (1) BG107834A (ja)
BR (1) BR0206502A (ja)
CA (1) CA2435121A1 (ja)
CR (1) CR6983A (ja)
CZ (1) CZ20031853A3 (ja)
DO (1) DOP2002000325A (ja)
EA (1) EA200300537A1 (ja)
EC (1) ECSP034692A (ja)
EE (1) EE200300335A (ja)
GB (1) GB0101223D0 (ja)
GT (1) GT200200003A (ja)
HU (1) HUP0302767A2 (ja)
IL (1) IL156087A0 (ja)
IS (1) IS6818A (ja)
MA (1) MA26980A1 (ja)
MX (1) MXPA03006408A (ja)
NO (1) NO20033223D0 (ja)
OA (1) OA12440A (ja)
PA (1) PA8537101A1 (ja)
PL (1) PL362793A1 (ja)
SK (1) SK8572003A3 (ja)
SV (1) SV2003000849A (ja)
TN (1) TNSN02003A1 (ja)
WO (1) WO2002056871A2 (ja)
ZA (1) ZA200304180B (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133931A1 (en) * 2001-12-21 2003-07-17 Robin Thurmond Use of histamine H4 receptor antagonist for the treatment of inflammatory responses
MXPA05002577A (es) * 2002-09-06 2005-09-20 Johnson & Johnson Uso de moduladores del receptor h4 de histamina para el tratamiento de alergia y asma.
US20050090527A1 (en) * 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
US8236786B2 (en) * 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
HUE039713T2 (hu) 2012-06-08 2019-02-28 Sensorion H4 receptor inhibitorok tinnitus kezelésére

Also Published As

Publication number Publication date
JP2004517883A (ja) 2004-06-17
BR0206502A (pt) 2003-10-21
TNSN02003A1 (fr) 2005-12-23
HUP0302767A2 (hu) 2003-11-28
ECSP034692A (es) 2003-08-29
CR6983A (es) 2003-11-25
GB0101223D0 (en) 2001-02-28
EP1353657A1 (en) 2003-10-22
MXPA03006408A (es) 2003-10-15
CZ20031853A3 (cs) 2004-07-14
KR20030069216A (ko) 2003-08-25
IS6818A (is) 2003-05-15
ZA200304180B (en) 2004-06-15
WO2002056871A2 (en) 2002-07-25
BG107834A (bg) 2004-01-30
SK8572003A3 (en) 2004-07-07
PL362793A1 (en) 2004-11-02
IL156087A0 (en) 2003-12-23
AR032101A1 (es) 2003-10-22
EE200300335A (et) 2003-12-15
PA8537101A1 (es) 2002-08-29
SV2003000849A (es) 2003-01-13
MA26980A1 (fr) 2004-12-20
CN1486178A (zh) 2004-03-31
OA12440A (en) 2006-05-22
EA200300537A1 (ru) 2004-02-26
NO20033223L (no) 2003-07-16
DOP2002000325A (es) 2003-01-31
GT200200003A (es) 2002-08-19
AP2002002401A0 (en) 2002-03-31
NO20033223D0 (no) 2003-07-16

Similar Documents

Publication Publication Date Title
CN1784221B (zh) 影响体重减轻的组合物
Barnes The role of anticholinergics in chronic obstructive pulmonary disease
Maesen et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group
EP1718336B1 (en) Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
US20020052312A1 (en) Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
KR20000029975A (ko) 히스타민수용체길항제의배합물을사용한상부기도알레르기반응의치료
HUT74949A (en) Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists
AU731447B2 (en) The topical use of kappa opioid agonists to treat ocular pain
AU2008259864B2 (en) Methods and compositions for administration of Oxybutynin
US20220218672A1 (en) Thromboxane Receptor Antagonists in AERD/Asthma
CA2435121A1 (en) Histamine receptor antagonists
US20020132755A1 (en) Histamine receptor antagonists
AU2002216328A1 (en) Histamine receptor antagonists
AU2008333220B2 (en) Mequitazine for treating or preventing pathologies involving histamine H4 receptors
Fassoulaki et al. Flumazenil reduces the duration of thiopentone but not of propofol anaesthesia in humans
WO2007145874A1 (en) Anti-nicotine treatment comprising use of three anticholinergic agents
Bauer et al. Bradykinin modulation of a spinal nociceptive reflex in the rat
JPH1160483A (ja) Tnf産生阻害剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued